What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Gesundheit & MedizinOne-Off10Mon
Manifold MarketsKein KYCVerifizierte AuflösungsdatenGut kalibriertAktuelle Community-Prognose60-69% 25.7%Führend unter 7 Optionen
Prognostiker
15
Fragetyp
multiple choice
Methodik
Play-money forecasting platform
Quellentyp
Prognose
7d-Änderung
+0.1 pts
Marktdaten
Aktualisiert vor 17 Stunden
Veraltet15. März 24, 21:29 UTC2. Sept. 27, 06:59 UTC
Trends
Verwandte Märkte
Verwandte Fragen als Kontext, kein Vergleich gleichwertiger Kontrakte.
What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 24 months?
Manifold MarketsWill molecular jackhammers have at least 50% tumour-free efficacy in Phase 2 clinical trials?
Manifold MarketsHantavirus pandemic in 2026?
PolymarketMeasles cases in 2026?
KalshiMeasles cases in U.S. in 2026?
PolymarketMeasles cases in U.S. by October 31?
PolymarketRegeln
The 12 month phase 3 data indicates 75% vaccine efficacy of R21 in annual malaria sites in children at 12 months after the first dose was delivered.
- Phase 2b data at a 42 month timepoint showed 71% efficacy after four total doses (Abstract here, #6949).
- Resolves upon publication of peer-reviewed data from the R21 team at Oxford (expected to be before September 1st, 2026).
- Vaccine efficacy is defined as the primary endpoint for time to clinical malaria in seasonal sites, as defined in the paper linked above.
- 1Day Sooner has an R21 Status Report available here that may be useful.
- More malaria-related questions can be found on our Manifold account here.